featured
2024 Top Story in Neurology: Phase II Study of Subcutaneous Efgartigimod for CIDP — Promising Results but Study Design Is Challenging and Efficacy Data Need Bolstering
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Allen JA, Lin J, Basta I, et al. Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (ADHERE): A Multicentre, Randomised-Withdrawal, Double-Blind, Placebo-Controlled, Phase 2 Trial. Lancet Neurol. 2024;23(10):1013-1024.
- Dalakas MC. Advances in the Diagnosis, Pathogenesis and Treatment of CIDP. Nat Rev Neurol. 2011;7(9):507-517.
- Dalakas MC Spaeth PJ. The Importance of FcRn in Neuro-Immunotherapies: From IgG Catabolism, FCGRT Gene Polymorphisms, IVIg Dosing and Efficiency to Specific FcRn Inhibitors. Ther Adv Neurol Disord. 2021;14:1756286421997381.
- Dalakas M, Engel WK. Immunoglobulin Deposits in nerves of patients with Chronic Relapsing Polyneuropathies. Arch Neurol. 1980;37(10):637-640.
- Askanas V, Engel WK, Dalakas M. Human Schwann Cells in Tissue Culture: Histochemical and Ultrastructural Studies. Arch Neurol. 1980;37(6):329-337.
Disclosure statements are available on the authors' profiles: